

2/2022

SOCIETY

MEETING

EDUCATION

IASIOS
continues
to expand

Getting ready for
the IR meeting
of the year

ESIR travels
to Munich

IR
news

WELCOME TO
CIRSE 2022

Cardiovascular and Interventional Radiological Society of Europe

Content

- 1 Lines from the President
- 2 Committee Election Results
- 3 Standards of Practice
- 4 CIEMAR
- 5 CIRT
- 6 Next research
- 8 RESPECT
- 9 CVIR Endovascular
- 10 CVIR
- 12 IASIOS
- 14 ECIO 2022 review
- 16 ET 2022 review
- 18 Welcome to CIRSE 2022!
- 20 Awards and honours
- 21 Award of excellence
- 22 ETF
- 23 CIRSE Students
- 24 CIRSE Academy
- 25 CIRSE Library
- 26 CIRSE Webinars
- 28 ESIR

CIRSE Central Office | Neutorgasse 9, 1010 Vienna, AUSTRIA
Tel: + 43 1 904 2003, Fax: + 43 1 904 2003 30, info@cirse.org, www.cirse.org

© All rights reserved by
CIRSE – CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGICAL SOCIETY OF EUROPE / 2022

Editorial Board: CIRSE Executive Committee | Managing Editor: Elizabeth Wenzel, CIRSE Office
Graphics: LOOP.ENTERPRISES media, www.loop-enterprises.com

Disclaimer

IR News is designed to provide information on the activities, congresses and educational ventures of the Cardiovascular and Interventional Radiological Society of Europe (CIRSE). While the information in this publication is believed to be true, neither the Editorial Board nor the Editorial Team can accept any legal responsibility for any errors or omissions made. All contributors are responsible for ensuring that submitted articles are their own original work. Contributed articles do not necessarily reflect the views of the IR News or of CIRSE.

CIRSE has enjoyed an exciting first half of 2022, with all congresses and events returning to an in person format.

Dear colleagues,



The first half of 2022 has been a breath of fresh air after two years in various states of lockdown. While we continue to improve and expand our online and remote educational opportunities, it has been thrilling to once again be able to meet, share and connect in person.

Nice to see you again!

We have already hosted several successful events this year in person, including ECIO, ET, IROS, and three ESIR courses! Though pandemic-related challenges remain, in many regards it feels as if we've never been apart. Spirits across the board have been high as we finally have been able to personally reconnect with so many colleagues and friends from afar.

To mitigate the difficulties in transitioning back to 'normal,' and in recognition that travel often remains challenging, ECIO and ET were again offered in a hybrid format featuring custom-built educational platforms. A review of both congresses is included in the following pages.

A good year for our initiatives

Next Research, CIRSE's full-service contract research organisation, is now in its second year. So far, data from CIREL and CIRT has been presented at ET 2022, and CIREL also presented at ESMO-GI at the end of June. Data from CIREL, CIEMAR and RESPECT will all be presented at CIRSE 2022 in Barcelona – flip to page 6 to learn more.

IASIOS, the International Accreditation System for Interventional Oncology, is also in its second year after their April 2021 public launch. The strong growth trend shown in its first year has continued until the present, and there are now 33 participating centres spanning hospitals across the globe, with several more registered or at the beginning of the enrolment process. Page 12 has all the details!

Even as we enjoy meeting again in person, the pandemic did demonstrate the value of easily accessible, high-quality online educational offerings. The CIRSE Academy and Library have both been expanded, and the webinar series that started in response to the pandemic has become a successful ongoing initiative. Read more about CIRSE's online educational offerings starting on page 24.

CIRSE 2022 – Science for people

The world's biggest IR meeting is just around the corner, and we are thrilled to head back to Barcelona! Featuring PAD Day and IDEAS, CIRSE 2022 will include all the quality educational programming you've come to expect. We are especially excited to once again be able to offer more collaborative session types in person – more than 60 hands-on device trainings will take place during the congress!

As with ET and ECIO, CIRSE 2022 also features a custom-built online platform where delegates unable to join us in person can watch livestreamed content or access lectures on demand. Turn to page 18 for a more in-depth view of what awaits you at the IR congress of the year.

2022 elections

Thank you to all members who took part in the 2022 committee elections last May! I extend my congratulations to the newly elected officials to the Executive Committee and standing committees. Their terms of office will commence after the 2022 General Assembly – and I will hand the reigns of the CIRSE presidency over to my friend and colleague, Prof. Christoph Binkert.

I hope that you enjoy reading about all of the current CIRSE activities in the following pages as much as I enjoyed being involved in them. I cannot think of a more fitting conclusion to my presidency than to see you all, at last, in person at CIRSE this September!

Afshin Gangi
CIRSE President

The results are in – we are happy to announce CIRSE's Committees for 2022-2024!

CIRSE committee election results

The CIRSE Executive Committee would like to thank all members who took part in the 2022 committee elections, held from May 30-June 10. In total, 891 members cast their votes.

We would like to thank all members who applied for positions in the Executive Committee and the standing committees, and congratulate the newly elected officers. Their terms of office will commence after the 2022 General Assembly.

CIRSE Executive Committee

(term of office: September 2022-2024)

President	Christoph Binkert
Vice-President	Philippe Pereira
Treasurer	Stefan Müller-Hülsbeck
Past President	Afshin Gangi
Scientific Programme Committee Chairperson	Adam Hatzidakis
Scientific Programme Committee Deputy Chairperson	Gerard O'Sullivan
Standards of Practice Committee Chairperson	Alex Barnacle
Research Committee Chairperson	Thomas Kröncke
Membership Committee Chairperson	Raman Uberoi
EBIR Committee Chairperson	Colin Nice
CVIR Editor-in-Chief	Klaus Hausegger
Online Education Committee Chairperson	Dimitrios Filippiadis
CIRSE 2023 Local Host Committee Chairperson	Arindam Bharadwaz
ECIO 2023 Scientific Programme Committee Chairperson	Philippe Pereira
ET 2023 Scientific Programme Committee Chairperson	Patrick Haage
Executive Director	Daniel Waigl

CIRSE Standing Committees

Membership	Marco Das, Athanasios Diamantopoulos, Francesco Giurazza, Christian Hohl, Jernej Lučev
Standards of Practice	Antonio Basile, Tiago Bilhim, Yuri Gupta, Pramod Prabhakar Rao, Anthony Ryan
Research	Roberto Luigi Cazzato, Fernando Gómez Muñoz, Anna Maria Ierardi, Ulf Teichgräber, Thomas Vogl

More information on the 2022 CIRSE Executive Committee Elections can be found in the myCIRSE area.

Though the last years have been challenging, they have resulted in a record number of new SOP documents!

Standards of practice documents



The CIRSE Standards of Practice Committee is tasked with creating robust documents which recommend best practices for performing specific interventional radiological treatments and techniques. These draw on existing literature, as well as the on-the-ground experience and recommendations of international experts who are specially recruited to create the documents.

The SOP Committee is also tasked with regularly updating existing documents to ensure their continued accuracy.

The members of the respective writing groups are chosen to ensure not only expertise in the given clinical sphere, but also to reflect a broad cross-section of European practice. This warrants that the consensus recommendations for the provision of IR services are valid throughout Europe and beyond.

The documents are aimed at both experienced and novice IRs, as well as providing a useful reference for physicians from other medical specialties.

In 2020, the pandemic and the attendant change in working practices resulted in a record number of SOP publications; the highly motivated SOPC that is currently in office has continued this positive trend despite resuming normal clinical loads, and five high-quality SOP documents were published in CVIR in 2021 as well as two more so far in 2022.

The following standards of practice guidelines were published in CVIR over the last two years:

- CIRSE Standards of Practice on Bronchial Artery Embolisation
J. Kettenbach
- CIRSE Standards of Practice on Thermal Ablation of Bone Tumours
A. Ryan
- CIRSE Standards of Practice on Peri-operative Anticoagulation Management During Interventional Radiology Procedures
M. Hadi/R. Uberoi
- CIRSE Standards of Practice on Conducting Meetings on Morbidity and Mortality
J.-Y. Chun
- CIRSE Standards of Practice on Below-the-Knee Revascularisation
S. Spiliopoulos
- CIRSE Standards of Practice on Percutaneous Transhepatic Cholangiography, Biliary Drainage and Stenting
M. Das
- CIRSE Standards of Practice on Hepatic Transarterial Chemoembolisation
P. Lucatelli

For a full list of all of CIRSE's standard of practice documents published since 2003, please visit:
www.cirse.org/education/standards-of-practice



SOPC members at CIRSE 2019
(Not pictured: Pierleone Lucatelli and Raman Uberoi)

Standards of Practice Committee

Laura Crocetti | *Chairperson*

Joo-Young Chun
Elika Kashef
Pierleone Lucatelli
Anthony Ryan
Stavros Spiliopoulos
Raman Uberoi (ex-officio)

The CIRSE Emprint Microwave Ablation Registry is currently enrolling.


CIEMAR pushes for 500 patients

CIEMAR

CIEMAR is a prospective, single-arm, multi-centre observational study that aims to observe the real-life use of microwave ablation treatment for patients with colorectal liver metastases in Europe. The primary objective of the study is to assess the effectiveness of microwave ablation performed with the Emprint or Emprint HP device in controlling colorectal metastatic tumours in the liver.

From September 2019 until today, the CIEMAR registry has enrolled 426 patients from 35 hospitals across Europe. Since the pandemic slowed down the enrolment pace, CIEMAR is far from reaching its final milestone of 700 patients enrolled.

The registry needs to reach at least 500 patients before the end of patient and hospital recruitment on January 31, 2023. To ensure that, the CIEMAR team is working on enrolling new centres and following up with participating hospitals to make sure all eligible patients are included in the study and also monitor the data quality.



Top CIEMAR recruiters

The highest CIEMAR recruiters are the Netherlands, Italy, North Macedonia, Germany, Norway, Greece, Spain, Turkey, Portugal and France, with more than six patients enrolled each.

The Amsterdam University Medical Center is in first place with 79 patients enrolled, followed by the City General Hospital 8th September and the European Institute of Oncology with 30 patients each.

We want to thank all involved hospitals for their hard work!

If you are interested in participating in CIEMAR or would like to receive further information on the research project, please contact:

Anna Kafkoulas | CIEMAR project manager
+43 1 904 2003 54 | ciemar@cirse.org | kafkoulas@cirse.org

CIRT was the first prospective observational study sponsored and conducted by CIRSE.

A big THANK YOU to all CIRT participants



The CIRT Steering Committee and CIRSE Society want to thank all the investigators, sub-investigators, study nurses and other site staff involved in the CIRT study on the real-world application of transarterial radioembolisation (TARE) for their commitment, hard work and dedication to this outstanding project. Without you, it would not have been the success that it is now.

The CIRSE Registry for SIR-Spheres Therapy (CIRT) was the first prospective observational study sponsored and conducted by the CIRSE Society. Spearheaded by Prof. Nacho Bilbao (Pamplona, ES) and then Prof. Thomas Helmberger (Munich, DE), the CIRT study was received with enthusiasm and fervour by the IR community and ultimately paved the way for other studies with similar study designs, such as CIREL (chemoembolisation) and CIEMAR (microwave ablation). Moreover, the continuous interactions between site staff, steering committee and project management resulted in a solid data set that tackles the questions from the IR community concerning the optimisation of the clinical application of TARE.

With more than 1000 patients from 27 sites in 8 countries, CIRT is the largest prospectively collected data set on patients treated with TARE in Europe and a good

representation of patients treated with this modality. Following the first data presentation at CIRSE 2020 and subsequent publication in CVIR, additional findings and subgroup analyses have been shared with the medical community throughout 2021. Currently, several publications are in the making and can be expected to be available open access in the third quarter of 2022. We expect these publications to make a splash and improve the optimisation of patient selection and clinical application of TARE. This could not have been possible without your tireless work and efforts to collect the necessary clinical data.

Of course, the success of CIRT has only triggered further discussion about the potential of this data set to design further studies in TARE. Currently, proposals for follow-up studies are being discussed and additional analysis of the CIRT data is ongoing to support these proposals. Stay tuned for more updates!

For now, the CIRSE Society and the CIRT Steering Committee want to wholeheartedly thank you for the years of fruitful collaboration and for showing that IR is dedicated to evidence-based medicine and patient care!

InterventionalNews

A specialised news source in the interventional field

NEXT RESEARCH

Next Research is a contract research organisation (CRO) established and owned by the CIRSE Foundation, dedicated to promoting evidence-based medicine in interventional radiology.

Next Research at ET, ESMO-GI and CIRSE 2022

Next Research at ET 2022 – The European Conference on Embolotherapy

Moderated by Philippe L. Pereira and Thierry de Baere, Next Research hosted a symposium at ET to discuss evidence and research gaps in embolization.

The following topics were presented:

- Current research needs in TARE & data gaps identified by CIRT – T. Helmberger
- Current research needs in TACE & data gaps identified by CIREL – R. Iezzi
- Hot topic: hemorrhoidal artery embolization – C. Binkert

The first publication of the main results aims to illustrate the real-world use with regard to patient cohorts, feasibility, safety and tolerability. At ET in Nice, Pierlone Lucatelli (Sapienza University of Rome, Italy) presented a summary of the most important findings regarding the use of irinotecan-TACE in CRLM patients. Notably, 70% of CIREL patients were treated in non-salvage settings, and therefore beyond guideline recommendations for CRLM. He also showcased the good tolerability of the treatment and presented his peers with findings about which patients and which treatment characteristics are associated with an increase in adverse events. The results from CIREL furthermore emphasize the importance of per-procedural medication.



Pictured: the moderators and presenters together with Next Research team members

CIREL at ET 2022 – The European Conference on Embolotherapy

After four years of data collection, CIREL – the real-life observational study on the use of irinotecan-TACE in colorectal cancer liver metastases – has closed and is now preparing the database lock for publication of the main results. The steering committee members and principal investigators have already started to communicate highlights, important results and lessons learned from CIREL.

"All centres work differently, but they all do something to manage pain. Otherwise, an irinotecan-TACE treatment would fail and the patient could drop out of the treatment schedule."

Dr. Pierlone Lucatelli
CIREL Investigator
Sapienza University of Rome/IT

Data from CIREL, CIEMAR and RESPECT will be presented at CIRSE 2022!



CIREL at ESMO-GI 2022 – ESMO World Congress on Gastrointestinal Cancer

We are happy to report that the results of the CIRSE-sponsored research project, CIREL, were presented at ESMO-GI for the first time. Co-Chairperson and oncologist Julien Taieb (Georges Pompidou European Hospital, Université de Paris, France) presented a poster illustrating interim effectiveness results.



CIREL, CIEMAR & RESPECT at CIRSE 2022

Next Research's abstracts for the observational cohort studies CIREL, CIEMAR and RESPECT have been accepted as oral presentations and will be presented at CIRSE 2022 from September 10-14 in Barcelona, Spain.

Browse the full programme here.

CIREL

The CIREL abstract will be presented by the Co-Chairperson Prof. Philippe L. Pereira from the SLK-Kliniken Heilbronn GmbH in Germany, under the title *'Early and long-term effectiveness results from CIREL, the multi-centre observational study on irinotecan-TACE in CRLM'* during the session on Transarterial chemoembolization hepatocellular carcinoma (TACE HCC).

CIEMAR

The CIEMAR abstract will be presented by the CIEMAR Investigator Prof. Martijn Meijerink from the University Medical Centre Amsterdam in the Netherlands, under the title *'First look into CIEMAR: patient selection, treatment details and early safety data of the European-wide observational study on MWA in CRLM with curative intent'* during the session on Ablation of metastases.

RESPECT

RESPECT's abstract will be presented by its Chairperson PD Dr. med Attila Kovacs from the MediClin Robert Janker Klinik in Germany, under the title *'RESPECT: a new Europe-wide prospective multi-centre observational study evaluating the effectiveness of percutaneous electrochemotherapy for liver cancer'* during the session called Clinical trials in embolotherapy and interventional oncology: Meet the PI.

RESPECT will begin patient enrolment in September 2022.

RESPECT: the technique behind the study

RESPECT

Starting patient enrolment this September, the REgiSry on Percutaneous ElectroChemoTherapy (RESPECT) aims to assess the effectiveness of percutaneous electrochemotherapy (ECT) in controlling primary and secondary liver cancer.

Electrochemotherapy is a non-thermal local tumour ablation technique (LAT) that combines chemotherapy with transient permeabilization of the cell membrane by reversible electroporation, resulting in a drastic increase in cytotoxicity (Figure 1).

In the context of liver malignancies, ECT overcomes limitations encountered by more established LATs: Firstly, it predominantly targets rapidly dividing tumour cells causing very little collateral damage to neighbouring structures. Secondly, it is not affected by the heat-sink effect of large blood vessels, which strongly reduces the efficacy of thermal ablation. ECT is therefore recommended for unresectable lesions located close to critical structures.




Figure 1. Principle of ECT. For the treatment of liver malignancies, ECT is performed under general anaesthesia and muscle relaxation. The procedure includes the following steps:

- 1) Electrodes (2 to 8) are carefully placed at the site of the tumour following a software-based treatment plan to ensure maximum coverage of the target area.
- 2) A chemotherapeutic agent, usually Bleomycin, is delivered intravenously.
- 3) Short electric pulses are applied after the chemotherapeutic drug had time to diffuse into tissues, i.e., 8 minutes after injection.
- 4) The highly potent chemotherapeutic, which is poorly permeant under normal conditions, can easily pass the cell membrane and reach its intracellular target.

After the feasibility, safety and effectiveness of intraoperative ECT were proven in large cohorts of patients with liver cancer. Recent smaller studies have introduced percutaneous ECT as a minimally invasive treatment option. Sponsored by CIRSE and managed by its CRO, Next Research, RESPECT is a prospective, Europe-wide, multi-centre, single-arm observational study that will extend the current evidence base for the real-life effectiveness, safety and impact on quality-of-life of percutaneous ECT in a larger, more diverse population of patients with liver malignancies.

More information on RESPECT is available at www.nextresearch.org/respect or www.clinicaltrial.gov (ID: NCT05267080).

If you are interested in participating in RESPECT or would like to receive further information on the research project, please contact:

Claire Poulet | RESPECT project manager
respect@cirse.org | poulet@cirse.org

The reviewer forum allows qualified candidates to get on the fast track to editorial board membership.

CVIR Endovascular – an interview with one of the editorial board members



The CVIR Endovascular reviewer forum is a three-year programme where highly qualified candidates can earn a spot on its editorial board. The application period for this year has now closed, but we would like to thank the many, many motivated doctors who reached out to us!

We were fortunate to have our newest editorial board member, Dr. Ramin Pourghorban, talk to us about his experience with CVIR Endovascular's reviewer forum.

How did you become an IR?

Pourghorban: After completing four years of radiology training in Iran, I took a one-year interventional radiology fellowship in Tehran at the largest national university hospital in Iran. Then, I received an educational grant from the European Society of Radiology to participate in a three-month abdominal interventional radiology fellowship at Klinikum Darmstadt in Germany. I also took an additional neurointerventional course at Pierre Paul Riquet Hospital in Toulouse. After returning to Iran, I worked as the assistant professor of diagnostic and interventional radiology at Tehran University of Medical Sciences for two years before moving to Australia. So, I have been trying to learn from every opportunity and to hone my skills and improve my knowledge in diagnostic and interventional radiology.

What is the most important aspect of a good peer review?

Pourghorban: Peer review is essential to ensure that reliable data and meaningful conclusions can spread in a scientific community. I found it beneficial not only to the readers of a credible journal, but also to the authors, as they can improve their manuscript, consider the critiques for the next phase of their study, and learn from mistakes. It also gives the opportunity to the reviewers to get in touch with the ongoing researches in the field, keep themselves updated, communicate with the authors, and compare their own reviews with others.

How would you describe your experience of joining the reviewer forum to now being part of the editorial board for CVIR Endovascular?

Pourghorban: I found the idea of becoming a member of the editorial board after some dedication to the journal quite creative. I was very excited when I sent my resume to CVIR Endovascular and Prof., Jim Reekers generously gave me this opportunity to become part of the team. Being promoted from a reviewer to an editorial board member was a rewarding process.

What do you like to do when you're off the clock?

Pourghorban: I enjoy spending time with my lovely wife, and I am excited as I am further improving my career after moving to Australia. It has been a long journey till now, but cannot wait for the next chapters.

The CIRSE Journals Scientific Writing Workshop

A huge thank you to both speakers and participants for making this workshop a success!

The Scientific Writing Workshop was co-hosted by CVIR and CVIR Endovascular and took place over one and a half days before ET 2022 in Nice, France. Participants were guided through the ins and outs of scientific publishing and given hands-on training on diverse topics from manuscript structure and effective writing to publication ethics and reporting guidelines.

Editors-in-Chief Klaus Hausegger and Jim Reekers were joined by CVIR editors Tiago Bilhim, Laura Crocetti, and Refaat Salman, as well as our esteemed guest speaker with decades of experience, Dr. John Carpenter. It was a special opportunity for interventionists at different stages of their careers to gain feedback and interact with so many distinguished speakers at once. Participants are also eligible to claim CME credits for the event!

The group of attendees was an internationally diverse, motivated and open group who made the workshop interactive and enjoyable for all present. We would like to thank both speakers and participants for taking time to not only attend, but to thoughtfully connect and offer their experiences and perspectives.

You won't want to miss this special section edited by guest editor Dr. Tiago Bilhim!

Special section dedicated to TIPS

CVIR

CVIR's most recent special section, curated by Dr. Tiago Bilhim, was dedicated to TIPS. This collection of articles covers one of the most challenging interventional radiology procedures, transjugular intrahepatic portosystemic shunt (TIPS), written by renowned international voices in the field.

The special issue, "...also has a commentary from one of the most experienced and dedicated Interventional Radiologists going through TIPS history," writes Dr. Bilhim. "The question for all readers is – "Who" is the music band behind the scenes?"

The collection will address many topics, including the use of TIPS stent-grafts versus general stent-grafts, if the use of TIPS complicates medical procedures, and using the left jugular vein for a TIPS procedure. Post-TIPS hepatic encephalopathy is the most frequent and challenging complication, occurring in up to 30% of patients; therefore, this topic is an essential inclusion in this issue. Another important topic addressed in the section is whether thermal ablation of hepatocellular carcinoma (HCC) can be performed in patients with a TIPS.

The guest editor concludes in his editorial: "All and all, a great issue, and a great year for CVIR readers – enjoy!"

SPECIAL SECTION ARTICLES

Extra, Extra: Read all About it – This is TIPS Generation, Baby!

Tiago Bilhim & Klaus Hausegger

Comparison of the Covered Self-Expandable Viatorr CX Stent with the Covered Balloon-Expandable BeGraft Peripheral Stent for Transjugular Intrahepatic Portosystemic Shunt (TIPS) Creation: a Single-Centre Retrospective Study in Patients with Variceal Bleeding

Michael Schultheiss, Dominik Bettinger, Lukas Sturm, Arthur Schmidt, Johanna Backhus, Oliver Waidmann, Klaus Radecke, Daniel Grandt, Robert Thimme & Martin Rössle

Meet A New Boss, Not Quite The Old Boss

Ziv J Haskal

Clinical Outcomes of Transjugular Intrahepatic Portosystemic Shunt (TIPS) Creation Using Fluency Versus Viatorr Stent-Grafts: A Single-Centre Retrospective Study

Hua-Mei Wu, Song-Quan Huang, Yue-Meng Wan, Yu-Hua Li & Ying Xu

Single-Centre Retrospective Study Using Propensity Score Matching Comparing Left Versus Right Internal Jugular Vein Access for Transjugular Intrahepatic Portosystemic Shunt (TIPS) Creation

Zhenkang Qiu, Wenliang Zhu, Huzheng Yan, Guobao Wang, Mengxuan Zuo, Han Qi, Guisong Wang, Weiwei Jiang, Jingbing Xue, Fujun Zhang & Fei Gao

Hepatic Encephalopathy After TIPS Placement: Predictive Factors, Prevention Strategies, and Management

Xin Li, Sasan Partovi, Wendy Melissa Coronado, Sameer Gadani, Charles Martin, Dustin Thompson, Abraham Levitin & Baljendra Kapoor

Safety and Efficacy of Microwave Ablation for Hepatocellular Carcinoma in the Setting of Transjugular Intrahepatic Portosystemic Shunt

Jenny Yan, Xiaohan Ying, Anuj Malhotra, Adam Talenfeld, Resmi Charalel, Kyungmouk Steve Lee, David Trost & Andrew Kesselman

Liver Growth and Portal Hypertension Improvement After Percutaneous Recanalization of Chronic Portal Vein Thrombosis in Non-Cirrhotic Participants

Raphael Braz Levigard, Henrique Salas, Henrique Serrão, Felipe Diniz, Cristiane Alves Villela Nogueira, Alicia Araújo de Oliveira, Nathalie Carvalho Leite, Marcia Ladeira, Maria Chiara Chindamo & Gustavo Pereira

CVIR special sections increase topical interest and provide higher visibility for authors.



EXCLUSIVE INTERVIEW WITH THE GUEST EDITOR: TIAGO BILHIM

Why did you accept the invitation to become a guest editor for this special section?

Bilhim: I handled a series of interesting TIPS papers during the last months and together with CVIR's editor-in-chief, Professor Klaus Hausegger, we thought about bundling them all together in a dedicated print issue. I had to manage two TIPS papers drawing opposing conclusions and I thought it would be great to publish them "back-to-back". One concludes that dedicated TIPS stent-grafts are better, whereas another one concludes they work as well as other stent-grafts. Additionally, we had more TIPS papers in the pipeline, so it was just a matter of putting them up together. I also wanted to use this dedicated issue to encourage authors to look at last year's CVIR portfolio on TIPS and see what they might have missed. I believe that having these dedicated CVIR issues increases reader's interest and provides higher visibility for authors.

What did you hope to get out of this project?

Bilhim: We want to have the CVIR doors wide open to the global scientific community and encourage them to consider CVIR when submitting their original research. We also welcome editorials, commentaries and letters pertaining relevant topics for IRs regarding scientific research published within our journal, and selected relevant papers from other medical journals. These dedicated issues provide a huge impact for published studies within and outside our medical community. Our goal with these projects is to encourage all IRs to publish within CVIR – we are able to provide a fast and rigorous review, helping them to improve manuscript strength and guaranteeing high standards of scientific quality. If you publish with CVIR we will also be able to provide high visibility for your work, increasing the likelihood for future citations. On the other end of the scope, these issues increase interest for all CVIR readers. In a dedicated issue you get to learn a lot of new info on a specific topic, and works very well for authors and readers.

Take away tips for future guest editors:

1. Be passionate about the topic on your issue.
2. Know well the manuscripts included.
3. Invite amazing people to write amazing commentaries that will spark the interest of readers.

EXCLUSIVE INTERVIEW WITH: MICHAEL SCHULTHEIß

Bilhim: What are the biggest challenges when performing a TIPS procedure?

Schultheiß: There are multiple challenges concerning TIPS patients and TIPS implantation. It starts with pre-interventional aspects, such as patient selection and timing of TIPS, and goes on with the management of patients after TIPS, treating questions like reduction of diuretics or surveillance of hepatic encephalopathy. But the main challenge remains the TIPS procedure itself, which is technical highly demanding. I think the crucial point in any TIPS procedure is the portal puncture. Despite prior cross-sectional imaging, ultrasound guidance or different needle types, it remains the major difficulty of the procedure.

Bilhim: What are the main limitations with current stent grafts used for TIPS?

Schultheiß: At the moment there is only one licensed stent for TIPS implantation in Germany, a covered self-expanding nitinol stent. This stent is great, but has the disadvantage of a minimal diameter of 8mm. We learned that 8mm is better than 10mm, but in my opinion, for several patients a diameter < 8mm is required.

Bilhim: Why did you choose CVIR to present your work?

Schultheiß: Our group of interventional hepatologists regularly publishes in hepatological journals. In this community, interventional aspects of TIPS procedure are underrepresented. But I think that, even more than three decades after the first TIPS procedure, the technique needs improvement. CVIR is an excellent platform for the critical science exchange of TIPS interventionalists – real TIPS experts.

IASIOS continues to expand

Interventional oncology (IO) has been recognised as the fourth pillar in modern cancer care, offering significant benefits with minimally-invasive potential curative and palliative cancer treatments. Although IO is a promising young discipline, there is a lack of awareness of IO therapies among the general public and other medical specialists, which has represented a barrier to the field and its development.

The International Accreditation System for Interventional Oncology Services (IASIOS), the first of its kind in the world, was established to encourage the adoption of quality standards for IO on a global scale, accelerate the development of the field and increase the awareness of IO treatments and the facilities that offer them. The IASIOS accreditation system provides facilities with essential quality standards critical for patient safety and satisfaction. Achieving the IASIOS certification enables IOs to prove their value and expertise as primary clinical care providers to their patients, referring oncologists and hospital administrators. IASIOS Accredited Centres have demonstrated their commitment to providing the highest quality standards of patient care.

However, IASIOS is not only an accreditation system but also a membership programme, a global network of IOs and a supportive community interested and committed to growing the discipline and helping their patients. Apart from certifying their facility, IASIOS members have the opportunity to benefit from networking events, seminars, training sessions, surveys and benchmarking services.

Highly active and involved IO experts

Like the rest of the interventional oncology community, IASIOS and its Steering Board, participating centres, and council members have been active and busy with the reopening of in-person congresses in April 2022. The rapidly growing community is strongly dedicated to supporting and developing IO as a clinical discipline and demonstrating the importance of clearly established quality assurance standards.

In May, Prof Elias Brountzos, former CIRSE president and the first Greek IASIOS Enrolled Centre, gave a presentation about the IASIOS accreditation system, their experience and preparations, its value and significance at the annual Greek Oncology Society Meeting.

At the annual APSCVIR congress in June, Prof. Afshin Gangi, President of CIRSE and IASIOS Steering Board member and France's first IASIOS Accredited Centre, gave a talk about IASIOS, its current achievements and success. At the same congress, a special session on Quality Assurance in Interventional Oncology was organised, moderated by Professor Yasuaki Arai, IASIOS Council Member, and Prof Andy Adam, IASIOS Steering Board Chairperson and the world's first IASIOS Accredited Centre, who also gave a talk titled IASIOS: Why it's there and how it works. Prof Lizbeth Kenny, IASIOS Steering Board Member and IASIOS Enrolled Centre discussed lessons learned from Radiation Oncology. Prof. Bien-Soo Tan, IASIOS Council Member and the first Asian IASIOS Accredited Centre talked about how Singapore General Hospital implemented the IASIOS programme.

In early June, at the Sardinia Spine conference, Prof. Laura Crocetti, IASIOS Committee member and first Italian IASIOS Accredited Centre, gave a talk titled Gaining Recognition for Interventional Oncology, where she explained the importance of being able to certify your expertise through the IASIOS accreditation programme.

The IASIOS team was on-hand with booths to answer any questions and help get centres making the initial steps to getting enrolled, host "Ask Me Anything" sessions and personalised consultations at the ECIO Congress in Vienna, Austria, IROS Congress in Salzburg, Austria and ET Congress in Nice, France. They look forward to CIRSE 2022 and welcoming further inquiries and future IASIOS centres.



Visit the IASIOS booth at CIRSE 2022 to learn how you can get started!



Continued success and membership growth

The strong trend toward rapid growth that IASIOS has seen since its public launch a little more than a year ago has remained. Since its launch in April 2021, accredited, enrolled, and incoming IASIOS centres have tripled, increasing from 12 to 33 centres. IASIOS Accredited Centres span the globe, including hospitals in Europe, Turkey, Australia, and Singapore.

Several more centres have registered or begun their enrolment process. IASIOS is thrilled to welcome Attikon Hospital, the first IASIOS Enrolled Centre from Greece, Helios Wuppertal hospital in Germany, and the European Institute of Oncology in Italy. They have all joined as IASIOS Enrolled Centres.

Several more have begun the process of registering and getting initial consultations from the IASIOS team, funding approval or assistance from their quality assurance departments, including the first hospitals from the Middle East, North America and South America; as well as the first hospitals from Belgium, the Czech Republic, India, Ireland, New Zealand, Portugal, and Spain.

In addition, three hospitals have completed and submitted their applications – the University Hospital Torino, the University Hospital Southampton, and Università Cattolica del Sacro Cuore e la Fondazione Policlinico Universitario A. Gemelli IRCCS, an outstanding achievement for all three which have completed the entire process in less than six months!

It also must be noted that the Italian community has shown a firm commitment to accrediting their IO service lines with almost 20% of the IASIOS participation, an admirable and remarkable dedication to providing certifiable quality patient care.

Join the IASIOS community

Are you looking to become a member of the IASIOS community and get your IO service line accredited? Contact the IASIOS team at office@iasios.org to set up a personal consultation on how you can get started, or visit their website at www.iasios.org, for a step-by-step guide to getting started.

Testimonials



"The Wesley Hospital is proud to have been the first centre in the Southern Hemisphere to achieve IASIOS accreditation. The IASIOS brand affirms the high-quality service that the team provides to patients and referrers, and we look forward to continuing to find new ways to promote the highest standards of patient care."

Dr. Nicholas Brown and team



"IASIOS has assisted our facility in adhering to the gold standard of patient care and provision. As the first internationally accredited IO facility in Switzerland, Kantonsspital Winterthur is at the forefront of this evolving discipline."

Prof. Christoph Binkert and team

The European Conference on Embolotherapy returned to an in person format last April.

ECIO 2022: shining a spotlight on interventional oncology

From April 24 through 27, doctors from around the world met in Vienna, Austria, to discover new technologies and research in IO while interacting with leaders in cancer treatment and connecting with colleagues from around the world.

As interventional oncology continues to gain momentum, this conference is more vital than ever. It was thrilling to once again be able to hold an onsite meeting, the first in-person CIRSE congress held since before the pandemic. This year's programme included four days jam-packed with more than 150 lectures and 20 hands-on sessions.

As logistical challenges remained worldwide, ECIO was also held as an online meeting via a custom-built platform allowing delegates to watch livestreams from Vienna as well as all lectures on-demand after their conclusion.



All content from ECIO 2022 is now available via the CIRSE Library!

Something for everyone – from general to specialised

The scientific programme committee, headed by Chairperson Philippe Pereira and Deputy Chairperson Laura Crocetti, were thrilled to welcome delegates to a meeting covering the entire spectrum of treatments that interventional oncology can offer to patients, from well-established therapies to the newest, most cutting-edge technologies.

The programme featured a variety of session types tailored to delivering the ideal learning experience, from clinical focus sessions providing updates on the latest evidence, to technical focus sessions and hands-on learning opportunities.

One of the key topics of ECIO 2022 was immuno-oncology and how it can be further combined with minimally invasive procedures. Two clinical focus sessions scrutinised where we currently are, reviewed the available data and discussed where the field is headed. A new Meet the PI session provided an additional platform for some of the driving forces behind current IO research. The Embocept study, ABC and ProActiv studies were covered, among others, illustrating the importance of increasing the evidence base for IO. More highlights included a multidisciplinary panel on the impact of IO on the CRC tumour board, a session on AI in IO, and lectures on state-of-the-art treatments in HCC.

The meeting also featured an increased number of hands-on device trainings, ensuring that all IOs wishing to practice on the latest devices could do so. This was especially welcome after two years of online meetings!

The IO Foundation Course

ECIO 2022 included the very first IO Foundation Course, a course for interventional radiologists wishing to break into the field of interventional oncology. The half-day course took place in Vienna the day before the start of ECIO and was designed to teach the main elements of oncology to trainees and young staff members practicing in the field. The course was led by expert faculty and offered sessions on lung cancer and lung metastases, HCC and liver metastasis, renal cell carcinoma and clinical practice in IO. The course will be repeated prior to ECIO 2023. To view the preliminary programme, **visit www.ecio.org**.



ECIO 2023 will take place from April 16-19 in Stockholm, Sweden!

ECIO

Collaborating against cancer

As in previous years, the Collaborating Against Cancer Initiative allowed IOs attending ECIO to bring a tumour board colleague along to the congress free of charge in order to promote multidisciplinary collaboration and help other specialties gain a better understanding of what IO can do. Several participants let us know how much they gained by accompanying their IO counterparts to the congress!

"I think it's a nice opportunity to see the world through the perspective of the interventional oncologist... And I think the interventional oncology is the future and we have to cooperate and collaborate with radiologists."
Dr. Rustam Aliyev, surgeon

"I think participating in this initiative will help our daily practice because we have day-to-day work together, but we usually communicate mostly on the telephone or through the computer so we don't really know each other. Coming to the congress together, getting to know each other personally and participating in educational sessions will definitely help our practice and will benefit our patients."
Dr. Soma Kempler, oncologist

ECIO 2023

ECIO 2023 will take place in Stockholm, Sweden from April 16-19, 2023.



The Scientific Programme Committee is already busy putting together a fantastic programme for ECIO 2023.

We look forward to welcoming you in Stockholm!



**ECIO 2022 Poster
Award winner:
Magna Cum Laude**

We spoke to the Sofia Ventura-Díaz about her team's award-winning poster at ECIO 2022!

Percutaneous tumour ablation guided by electromagnetic navigation system: a retrospective study

S. Ventura Díaz, A. Olavarria Delgado, J. Cobos Alonso, R. Romera Sánchez, J. Urbano García

What motivated the research behind your poster?

Ventura-Díaz: We wanted to share our experience with electromagnetic navigation systems and assess their applicability as an auxiliary tool for abdominal tumors ablation, regardless of radiologist experience.

Why did you decide to submit a poster to ECIO 2022? What was the experience like?

Ventura-Díaz: It was the perfect match for our research theme. We did not have any trouble with the website, and the abstract was very easy to submit.

Your poster was awarded Magna Cum Laude – what do you think made your poster stand out from the rest?

Ventura-Díaz: I think that we had the advantage of having a large database with lots of cases, and that the presentation was visually attractive.

We have concluded that EMNS (Imactis-CT®) helps radiologists reach those lesions non-visible in non-contrast studies and/or with high-risk locations. This reduces the number of complications regardless, of the radiologist's experience, and allows ablation as a valuable therapeutic option to many more patients.

Anything else you'd like to mention?

Ventura-Díaz: Thank you for rewarding our work!

The European Conference on Embolotherapy took place from June 22-25.

ET 2022 – it was Nice to be back!

The European Conference on Embolotherapy took place from June 22-25 in Nice, France. Ensuring that CIRSE members have access to the best possible education and most recent data in embolotherapy, CIRSE began hosting ET in 2019. After being transformed into an online meeting for 2021, this year's conference was finally able to take place in person. More than one hundred expert faculty members guided attendees through 108 sessions over the four congress days.

The conference covered the full gamut of embolotherapy topics from trauma management to minimally invasive treatment options for vascular and lymphatic malformations and haemorrhoids, and much more. Leaders in the field explored the latest research, tools and materials, as well as the future applications of these interventions, creating a space for both learning and debate, effectively kicking embolotherapy education into the next gear.

Exploring the latest in embolotherapy

The 2022 Scientific Programme Committee, headed by Chairperson Patrick Haage and Deputy Chairperson Otto van Delden, ensured that ET covered an extensive range of topics encompassing both new treatments, and established therapies. Neurointerventions, paediatrics treatments and joint treatments were of particular note. Other highlights included women's health, GI bleeding, embolisation in trauma, and case remedy sessions looking at how particularly challenging cases were approached.



ET 2022 invited participants to submit their abstracts for the first time ever. In all, 160 abstracts from around the world were submitted to the meeting.

Hands-on opportunities and workshops were certainly one of the best parts about being back onsite, allowing delegates to gain experience and learn about the newest devices and technologies in person. ET 2022 also brought in a wide array of industry representatives to share the newest state-of-the-art technology and innovations during both the technical exhibition and each partner's satellite symposium.

As in 2019, interactivity was a focus of the meeting. From e-voting to the presence of the moderator in the audience to the catch-box microphone, attendees were encouraged to participate and engage with the moderators, speakers, and their colleagues.

All ET 2022 lectures, symposia, and posters are now available via the CIRSE Library.





**ET 2022 Poster
Award winner:
Magna Cum Laude**

We spoke to presenting Author Gennaro Castiello about the motivations behind his team's award-winning poster.

Post-radioembolization non-contrast cone-beam CT as an early predictor of 90Y-resin microspheres distribution for the interventional radiologist: validation of the technique and comparison with nuclear medicine imaging

G. Castiello, M. Giuliani, P. Riu, F. Colucci, S. Zilahi de Gyurgyokai, G. Ventroni, R. Cianni

What motivated the research behind your poster?

Castiello: The main reason of the interest in the topic of the poster was certainly the curiosity about the potential use of increasingly advanced technologies in order to make interventional oncology procedures, in this case transarterial radioembolizations with Yttrium-90, safer and more effective. The usefulness of C-arm cone-beam CT is, in fact, widely established for the work-up of such procedures, but further applications need to be explored for the confirmation of technical and therapeutical success.

Why did you decide to submit a poster to ET 2022? What was the experience like?

Castiello: The European Conference on Embolotherapy is an international reference for sharing, debate and exchange of knowledge and evidence in the field of interventional radiology, so it was a simple decision to consider such a platform for the poster submission. Moreover, the on-site experience was remarkable in terms of organization and content.

Your poster was awarded Magna Cum Laude – what do you think made your poster stand out from the rest?

Castiello: All the posters at ET 2022 were exceptionally interesting and I would like to take this opportunity to congratulate my colleagues from all over the world. One of the reasons for the success of our work could be the intrinsic simplicity of applying said techniques in a real-world clinical setting, also to make them the subject of further and necessary investigations. However, I would like to thank the Scientific Committee for considering our work worthy of such a prestigious award.

Anything else you'd like to mention?

Castiello: I would like to thank all the colleagues from the Interventional Radiology Department of San Camillo-Forlanini Hospital in Rome and its Chief Dr. Roberto Cianni, for their invaluable collaboration and support.



We look forward to welcoming you in Barcelona!

Welcome to CIRSE 2022!

The interventional meeting of the year is nearly upon us! From September 10-14, CIRSE will return to Barcelona, Spain, to once again host the world's largest IR meeting in person. Reconnect with your colleagues, participate in cutting-edge sessions, get hands-on opportunities, and remember the inspirational spirit of a full CIRSE experience! One thing is certain; this year's programme is a must-see for all interventionalists!

CIRSE 2022 will cover the entire spectrum of interventional radiology topics, from well-established therapies to the latest hot topics, as well as the most recent data releases. The programme will feature a variety of session types, from focus sessions centring on the ins and outs of daily clinical practice, to case-based discussions and video learning sessions providing excellent learning opportunities, to round-table discussions honing in on the field's most current issues. Featuring PAD Day and IDEAS, CIRSE 2022 will feature more than 400 lectures across its eight clinical tracks.

Online access

With logistical barriers remaining for many, CIRSE 2022 will be hosted as a hybrid meeting. Online access is possible for registrants and Digital All-Access Pass holders, who will be able to watch all sessions streaming live from Barcelona. All lectures will be available for on-demand viewing shortly after their conclusion. The custom congress platform and all on demand content, including posters and lectures, will be available to all attendees even after the live days of the congress have concluded.

PAD Day



The first day of CIRSE 2022 will include a dedicated PAD track on September 10, focusing on all that's new in the treatment of peripheral arterial disease. Highlights will include sessions on plaque management, updates on below-the-knee intervention, the optimal scaffold in the SFA, and the largest ever FIRST@CIRSE session!

The most extensive FIRST@CIRSE session ever held will feature original papers and brand-new, ground-breaking studies presented by the researchers themselves. The first data releases from some of today's most innovative studies in PAD research, such as those from the PRIZER study, DEEPER LIMUS trial, MOTIV BTK clinical trial, and many more will be showcased in this must-see session.

IDEAS 2022

IDEAS

IDEAS, the Interdisciplinary Endovascular Aortic Symposium, will return for CIRSE 2022. This congress-within-a-congress will feature sixteen sessions examining all aspects of aortic treatment and promoting IDEAS' core principle of interdisciplinary collaboration.

Of particular note, two expert round tables will cover all aspects of AAA, and another ERT will focus on chronic aortic dissection. Focus sessions will look at the future of aortic interventions as well as daily challenges in dealing with iliac occlusive and aneurysm pathology. The popular "amazing aortic interventions and video learning sessions will once again be featured this year.

New this year, IDEAS 2022 will feature a hands-on planning course! During this training series, delegates will use reconstruction software to plan endovascular repair and make accurate sizing in order to choose the right stent graft needed for standard EVAR as well as fenestrated/branched EVAR. Export tutors will be on hand to answer any questions that may come up and will be happy to support the delegates during the planning process.

Get hands-on

With the thrill of being back in-person, it's only appropriate that CIRSE 2022 will offer the most extensive hands-on device opportunities offered to date. From closure devices to ports, from embolotherapy tools to thrombectomy, more than 90 combined hours of education will be, quite literally, at attendee's fingertips.



[Click here to see more about all hands-on device trainings!](#)



Radiation Protection Pavilion (RPP) 2022

The RPP 2022 will be the first in-person event organised by the Radiation Protection Subcommittee since 2019!

For the RPP 2022 under the slogan “Your radiation exposure – you can handle the risk!”, the subcommittee has prepared a radiation comprehensive programme addressing the issue of occupational exposure. Sub-topics will include, among others, how to use personal dosimeters properly, novel techniques such as virtual and wireless dosimetry and biodosimetry: basics and current applications. The RPP will once again bring together medical specialists and industry partners to inform and educate the IR community on the latest scientific as well as technical developments in the field of radiation protection and dose management.



Take a sneak peek... at the new congress website!

The CIRSE Annual Congress now has its own dedicated website! Everything members, attendees, industry representatives, and other interested parties need to know about the congress, registration, travel and much more are now available in one convenient location at **cirsecongress.cirse.org**.

There's quite a lot to explore on the new website – for example, get a glimpse at some of this year's programme highlights with articles from the respective lecturers. Read the articles and add the sessions directly to your calendar from the sneak peeks page!

Not yet registered for the congress? Still need a hotel? All information about registration, travel and trainee and student programmes can be found under the attend tab.

See you very soon!

We are eagerly anticipating welcoming attendees, faculty, and industry representatives in person in Barcelona! With the wealth of opportunities for connections and experiences onsite, the CIRSE 2022 is not to be missed.



All awards will be presented at the opening ceremony on September 10.



Awards and honours

Honorary lectures

Each year, the Andreas Grüntzig Lecture and the Josef Rösch Lecture are given by scientists whose contributions to IR, the development of interventional radiology, and CIRSE are widely recognised. Honouring the late German radiology legend Andreas Grüntzig, this eponymous lecture has been given by some of IR's most outstanding representatives upon invitation from the CIRSE Executive Committee. Boris Guiu will give the Andreas Grüntzig Lecture, *"Venous interventions in the liver of non-cirrhotic patients: pushing the limits"* on Sunday, September 11 at 14:30 CEST.

Since its introduction in 2003, the Josef Rösch Lecture has been given by a number of prominent interventional radiologists who have taken this opportunity to reflect on the status of interventional radiology and its various treatments.

This year's lecture, *"Paediatric IR: developing excellence in IR for our youngest patients,"* will be given by Alex Barnacle on Tuesday, September 13 at 14:30 CEST.



[Click here to see the full bios for both speakers.](#)

Awards



Prof. Mark Little will be awarded the CVIR Editors' Medal for the paper *"Genicular artEry embolization in patiEnts with oSteoarthrtiS of the Knee (GENESIS) Using Permanent Microspheres: Interim Analysis"*.

Awards

John Kaufman and Hervé Rousseau will receive the Gold Medal. Gold Medallists have made outstanding contributions to the practice and science of interventional radiology on an international scale. Gold Medallists also have significantly promoted the image and impact of the society by personal influence and international recognition.



[Click on the pictures of the honourees to read their full bios!](#)

Aghiad Al-Kutoubi, Anne Marie Cahill and Luigi A. Solbiati will join the ranks of distinguished fellows who are honoured by the society for having made exceptional contributions to the practice and science of interventional radiology.



The awards will be presented at the CIRSE 2022 opening ceremony on September 10 at 14:30 CEST.

Award of Excellence and Innovation in IR



We have a winner! Congratulations!

The Award of Excellence and Innovation in Interventional Radiology, sponsored by the Rolf W. Günther Foundation for Radiological Sciences, is awarded on a yearly basis for outstanding contributions to the advancement of interventional radiology. Since its establishment in 2012, this distinction has been granted to some of the most innovative physicians in the field. The recipient of the award will receive a certificate of merit as well as a cash prize of €6,000.

This year, the honour will go to Prof. William T. Kuo for his work on the *Excimer Laser-Assisted Removal of Embedded IVC Filters*, which included the development of a new concept and procedure and recognised treatment. Prof. Kuo will receive the award and be officially announced as the winner during CIRSE 2022 in Barcelona.

The Innovation

The innovation of *Excimer Laser-Assisted Removal of Embedded IVC Filters* is a new cutting-edge procedure that permits the safe removal on a cellular/molecular level (via 306 nm XeCl excimer laser) of many different IVC filters refractory to standard retrieval methods regardless of dwell time, including many permanent IVC filters.

The progress of this innovation and its recognition as an important treatment option were already summarized in numerous journals. In 2010, the first human case report was published in the *Journal of Vascular and Interventional Radiology (JVIR)*, and the innovative procedure led to creation of the Stanford IVC Filter Clinic – now a national and international referral centre dedicated to treating patients with embedded IVC Filters.

After studying further results on over 500 patients, the overall safety and efficacy of the laser technique was validated in 2020 and published in the *Journal of the American Heart Association*. In addition, the study validated a new force-gauge protocol demonstrating how routine force gauge use in conjunction with the excimer laser not only avoids complications associated with excessive force, but also allows successful filter removal to be achieved safely using significantly lower force. The laser technique was acknowledged and referenced by a multidisciplinary consensus panel as an advanced technique that may be used to treat patients suffering complications from an embedded IVC filter refractory to standard retrieval methods.

About the winner

Prof. William T. Kuo is a professor of radiology and interventional radiology at the Stanford University School of Medicine, California, USA. He is author or co-author of more than 54 research papers and has contributed to numerous reviews and text books. His interest in IVC filters and pulmonary embolism have long been inspired by European leaders in IR, especially Miguel A. De Gregorio, Professor Michael J. Lee, Professor Thomas Schmitz-Rode, Professor Christoph A. Binkert, Professor Stefan Müller-Hülsbeck, and of course Professor Rolf W. Günther. Their seminal work inspired him to pursue research and innovations in catheter-directed thrombolysis for acute PE and advanced IVC filter retrieval.



Rolf W. Günther Foundation
for Radiological Sciences

The ETF is back in person at CIRSE 2022!

The European Trainee Forum's 2022 activities

This year, thanks to the return of in-person events, the ETF Subcommittee had the opportunity to meet at ECIO last April to discuss their current projects, including the ETF activities planned for the upcoming CIRSE congress. Currently, the subcommittee is comprised of 46 members, one male and one female representative from 27 European countries who collaborate on various projects and help tailor the European Trainee Forum activities according to the feedback from their home countries. Among the main goals of the ETF in 2022 is to help bring together all young IRs-in-training and facilitate the creation of a European network within CIRSE to help young IRs pursue their future careers.

Supporting IRs-in-training at CIRSE 2022

In order to support young IRs and help them receive free registration to the CIRSE Annual Congress, CIRSE has once again initiated the IR Trainee Support Programme which will allow CIRSE junior members who submitted an abstract for this year's congress to attend CIRSE 2022 free of charge. The application process concluded in April, and thanks to this programme numerous trainees have already received their free registration to the congress. What's more, radiology residents or fellows from Europe who are younger than 35 and are presenting authors of a paper or poster which was accepted for presentation at CIRSE 2022 had the chance to apply for one of ten travel grants which are kindly provided by the Rolf W. Günther Foundation for Radiological Sciences. The application period for CIRSE 2022 has already ended and all accepted applicants have been notified.

All IR trainees who have missed the abovementioned opportunities can still benefit from significantly reduced congress registration rates!

What to expect from the ETF programme at CIRSE 2022

Attending CIRSE can help IR trainees boost their careers in numerous ways by helping them deepen their IR knowledge with engaging scientific sessions as well as fundamental courses. The ETF has planned four dedicated trainee sessions and four short talk sessions including lectures on various topics providing key competencies and valuable career advice. IR trainees will also have the opportunity to participate in hands-on device trainings

and to see and handle the newest IR devices exhibited by the leaders of the medical device industry. Attending the CIRSE 2022 Annual Congress is a unique opportunity for trainees to build their professional network and meet the opinion leaders of the European IR community. Last but not least, trainees will have the chance to engage in some fun activities, like proving their knowledge at a specially tailored ETF quiz.

CIRSE junior membership

CIRSE would like to encourage readers to spread the word about CIRSE junior membership among their colleagues! Junior members not only benefit from reduced membership and registration fees for all CIRSE events, but also have the opportunity to apply for CIRSE support programmes. For more information, please visit www.cirse.org/trainees.



The ETF Subcommittee tailors ETF activities to serve IR trainees throughout the continent while building a network of young IRs within CIRSE

What else do we have in store?

The CIRSE ETF has planned six webinars tailored specially for IR trainees and medical students. To watch the full series of past webinars, register for upcoming ones and get inspired by professional IRs, visit www.cirse.org/trainees/etf-webinars/

To learn more about the ETF and its activities, visit www.cirse.org/trainees and follow the ETF on Facebook, Twitter, and LinkedIn.



More than 2,200 medical students have participated in the CIRSE Student Programme to date.

CIRSE Student Programme – be inspiRed

CIRSE 2022 – a unique chance to experience the world of IR

CIRSE is coming back to its in-person annual congress with full power. As in past years, the society is looking forward to welcoming a significant number of medical students from all around the globe to its annual meeting, which through the years has introduced over 2,200 students to the world of IR.

As in previous years, the Student Programme will feature an IR lecture where members of the CIRSE leadership will provide students with an introduction to the field of IR and its applications in modern medicine.

Attending the mentoring breakfast at CIRSE 2022 will help students get a clearer vision of what training and career opportunities are available throughout Europe. This event will allow students to get to know young IRs from the ETF, and might perhaps be a key factor in their decision to pursue a career in IR!



Students will also have a unique opportunity to gain hands-on experience by attending one of the planned Hands-On Device Training sessions, Simulation Sessions or Learning Centre Workshops organised by CIRSE's industry partners.

CIRSE will repeat its "Students on Stage" session, which was a great success back in 2019, where six students who submitted exemplary abstracts will have the chance to present their work to their peers.

To make this experience even more fun and memorable, students attending CIRSE 2022 will also have a chance to experience some group collaboration and prove their knowledge gained during the congress by attending the students' quiz. Lastly, they can look forward to being invited to a specially organised social event to enjoy a more casual setting in which to network with their peers.



To further support students and help them participate, CIRSE will provide all medical students who have EU/EFTA citizenship with the chance to receive €200 travel support for CIRSE 2022. Those who qualify for travel support will automatically be considered upon completion of congress registration and notified accordingly via email. Grants are distributed on a first-come, first-served basis upon completion of registration.

CIRSE welcomes all involved in undergraduate education to spread the word and help make sure their students are aware of these opportunities.

For more information visit **www.cirse.org/students** and follow us on Facebook **www.facebook.com/CIRSEstudents**


The CIRSE Academy is growing... with more still to come this year!

The CIRSE Academy

The CIRSE Academy has been steadily growing over the past four years and now offers a total of 49 e-learning courses, ranging over eight different IR topics:

- Two courses on neurointervention, including one on arterial and neurointervention
- Four courses on IR management, including one specialist course on "Clinical practice in endovascular intervention"
- Six courses on aortic intervention, including two courses on aortic and arterial interventions and two specialist courses on "EVAR" and "TEVAR"
- Six courses on venous intervention, including one course on arterial and venous intervention
- Seven courses on interventional oncology
- Eight courses on embolisation
- Eight courses on non-vascular intervention
- 12 courses on arterial intervention, including two courses on aortic and arterial interventions, one course on arterial and neurointervention, one course on arterial and venous intervention and two newly released courses on "Management of upper extremity arterial disease" and "IR management of complications post-kidney transplantation".

There are even more courses to come in the second half of this year. Stay tuned and make sure to purchase your Digital All-Access Pass so you don't miss out on this quality educational content.



CIRSEacademy


Too busy to browse? Let the curated content at the CIRSE Library be your guide.

Check out our new online educational content!

CIRSE Library – Content for every IR, all year round

Over the last few months, new types of content have been introduced at the CIRSE Library to give time-strapped users quick suggestions on what to watch. Whether it's CIRSE Library-exclusive content, highlights in IR or our regular featured content, there is something for all levels of IR knowledge and experience to learn from.

This is in addition to our regular topic packages, frequently updated recommended EBIR preparation content, and of course, all CIRSE congresses and webinars, which are available free of charge for all CIRSE members and Digital All-Access Pass holders.



Highlights in IR

This brand new, CIRSE Library-exclusive content aims to provide maximum educational value in just five minutes. Expert colleagues talk through an interesting case in their field of expertise, from case history through the intervention itself, and present key discussion and take-home points.

Be sure to check in on a regular basis and subscribe to CIRSE's e-newsletter to make sure you never miss the next instalments.

Featured content

Our bi-weekly featured content comes directly from CIRSE members who share videos that were insightful for them in the hope to encourage fellow IRs to also learn from them. We make sure to provide a diverse array of topics to cover the whole spectrum of IR.

If you would like to be part of this initiative and recommend features yourself, please contact online.education@cirse.org for further details.

CIRSE library

Focused learning opportunities – live and on-demand and free of charge!


CIRSE Webinars

CIRSE offers a range of highly specialised, innovative and free content in the form of the CIRSE Webinars! CIRSE Webinars vary from an hour to a full working day and cover various aspects of interventional radiology practice. The webinars offer high-quality lectures, as well as interactive commented videos of interventions. The material is delivered by leading international experts in the field who also engage in lively follow-up discussions and address the questions and comments from the viewers who are always encouraged to actively participate.

Coming up next:

Register with CIRSE to make sure you don't miss any of the free webinars planned for 2022! We will send you updates about webinars on:

- Trauma and emergencies: interventional radiology perspective on October 21
- Pulmonary embolism sponsored by Penumbra
- Mastering lesion access
- Neuroendocrine liver metastases
- Content for IR trainees through ETF webinars on "IR in liver tumours" and "Aortic interventions"
- ...and many others



Many more webinars are already in the works for 2023, including a four-part series on musculoskeletal interventions.

Keep an eye on cirse.org and our social media channels for updates!

CIRSEwebinars



European Board of
Interventional Radiology



MORE ACCESSIBLE THAN EVER!

Sign up today and take the
EBIR examination in English,
Spanish or German!


Apply Now

March 23, 2023 | English, German

October 19, 2023 | English, Spanish

Submit your application online

For more information, please visit our website at
www.cirse.org/ebir



Cardiovascular and Interventional Radiological Society of Europe

ESIR held a successful course in Munich last May – and there's much more still to come!

The European School of Radiology

In May, thirty-seven participants from Austria, Belgium, France, Germany, Italy, New Zealand, Portugal, Romania, Sweden, Turkey, Ukraine, and the United Kingdom participated in the ESIR course on TACE in primary and secondary liver cancer. Tobias Jakobs hosted the course at the Barmherzige Brüder hospital in Munich, Germany. Over two days, participants and faculty members engaged in a comprehensive discourse on the staging and treatment algorithm of HCC and metastatic liver disease, specifically C-TACE, DEB-TACE and B-TACE, via lectures, discussions and video cases provided by Tobias Jakobs, Pierleone Lucatelli and Nicolas Villard.

On the second day, participants rotated through the following four hands-on workshops: Vascular flow model using drug-eluting beads; Building the right suspension; Which microcatheter and wire?; Transradial, transfemoral, and how to close. Simulators allowed participants to encounter and practice a selection of TACE cases throughout the conference.

What was remarkable about the course was the esprit de corps that emerged among the faculty members and participants during the case discussions, ensuring unforgettable ESIR experience.

"Being part of the ESIR course in Munich was an incredible experience. Gaining information about the latest data and technologies from all the renowned experts in the field and being able to practice at the hands-on sessions was a great opportunity. One of my favourite things about

the course was the live cases, where you got to see all the different approaches and how to deal with potential complications. I think you can learn a lot from the faculty's worst complications lectures. I think I will benefit greatly from the presenters' expertise and networking with other doctors from all over Europe."

Sophia Holzhauser

Participant, resident Barmherzige Brüder Krankenhaus Munich/DE

"I really enjoyed the ESIR course on TACE in primary and secondary liver cancer. To be frank with you: I was overwhelmed by the vivid and open discussion between junior interventional radiologists and the international experts. In my opinion, this is a strong argument in favour of workshops like ESIR, where people do not hesitate to ask questions. The lectures featuring the faculty's worst complications were also outstanding and provided so much information to learn from. Together with the live cases and the hands-on workshops, it was a fantastic format to get deeper insights into the complex topic of transarterial treatment of liver tumours."



Prof. Tobias Jakobs
ESIR course Local Host



The next ESIR course will take place in Utrecht from November 3-4!

Radioembolisation of liver tumours

Utrecht/NL, November 3-4, 2022



Radioembolisation is increasingly performed throughout Europe and is continuously evolving. This is driven by technical innovations, the current availability of three different types of microspheres, and increasing insights into the need for patient-specific dosimetry. In this exceptional ESIR course, "Radioembolisation of liver tumours," organised by Dr. Maarten Smits, Dr. Arthur Braat and Prof. Marnix Lam, attendees will learn about the fundamentals, latest evidence and techniques for performing radioembolization. Participants will be able to familiarize themselves with the range of techniques and products available and learn more about the latest developments in the field of radioembolisation. There will be plenty of opportunities for networking and time and to explore Utrecht's historic canals, so secure your spot and register today!

Hands-on liquid embolisation

Strasbourg/FR, November 17-18, 2022




In recent years, liquid embolics have increased in popularity among interventional radiologists, as these agents boast both high embolic efficiency and good clinical results. However, as liquid management and

technical aspects are different and more complex than using conventional coils or particles, the learning curve is difficult and, therefore, should be done first in animals. In this unique course, pigs will be used in the in-vivo workshops in order to learn how to deal with the injection of glue and EVOH into livers and kidneys. In the ex-vivo workshops, participants will practice on models to learn about the right way to use sclerosants, cyanoacrylate glue, and EVOH. Additional parallel stations will provide opportunities for participants to learn about the preparation and mixing of glue and EVOH. Organised by Prof. Christoph Binkert and lead by a team of expert faculty members, Dr. Emanuele Boatta, Dr. JY Chun, Dr. Bernhard Gebauer and Prof. Bernhard Meyer, this course will ensure that experienced IRs are up to date on this important and expanding facet of embolisation. This course is fully booked for 2022, but will return in 2023! Please contact office@esir.org for more information.

Reliability in percutaneous tumour ablation

Innsbruck/AT, December 15-16, 2022



Thermal ablation has been proven to be an effective method for the treatment of numerous tumour entities in various anatomical locations and has great potential to increasingly replace open or laparoscopic resection. In order to achieve maximal reliability, however, interventional oncologists must be properly trained in the application of the various available tools, imaging techniques and image fusion tools. This ESIR course organised by Prof. Reto Bale will give attendees an overview of the currently available devices and techniques in the field of percutaneous tumour ablation, enabling them to plan and perform procedures and conduct the corresponding follow-up. The Innsbruck course has proved popular in the past years, register today!

